Yahoo
NasdaqCM - Nasdaq Real Time Price USD

BioVie Inc. (BIVI)

1.4300 +0.0500 (+3.62%)
At close: October 30 at 4:00:01 PM EDT
1.3922 -0.0378 (-2.64%)
After hours: October 30 at 4:06:22 PM EDT
Chart Range Bar
Loading chart for BIVI
  • Previous Close 1.3800
  • Open 1.3900
  • Bid 1.1100 x 200
  • Ask 1.4500 x 100
  • Day's Range 1.3800 - 1.4900
  • 52 Week Range 0.8200 - 3.7900
  • Volume 105,818
  • Avg. Volume 4,588,484
  • Market Cap (intraday) 12.416M
  • Beta (5Y Monthly) 0.73
  • PE Ratio (TTM) --
  • EPS (TTM) -3.0500
  • Earnings Date (est.) Nov 9, 2026
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est 5.26

BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism. It also develops Bezisterim, an investigational, novel, orally administered small molecule that is In Phase 3 clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2b clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.

bioviepharma.com

13

Full Time Employees

June 30

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

BIVI
23.28%
S&P 500 (^GSPC)
10.73%

1-Year Return

BIVI
19.21%
S&P 500 (^GSPC)
11.11%

3-Year Return

BIVI
99.63%
S&P 500 (^GSPC)
81.91%

5-Year Return

BIVI
99.77%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue --
Earnings -5.09M
Profit Margin 0.00%

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

-6M
-4M
-2M
0
0.0%

Analyst Insights

View More

Analyst Price Targets

5.00
5.26 Average
1.4300 Current
5.51 High

Latest Rating

Date 7/1/2024
Analyst ThinkEquity
Rating Action Initiated
Rating Buy
Price Action Announces
Price Target 3

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -79.06%

  • Return on Equity (ttm)

    -150.76%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -22.12M

  • Diluted EPS (ttm)

    -3.0500

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    8.98M

  • Total Debt/Equity (mrq)

    2.68%

  • Levered Free Cash Flow (ttm)

    -11.12M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: